Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,359 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastrointestinal Cancer Metastatic Clear all

Conditions: Colorectal Neoplasms
Interventions: 1018 ISS immunostimulatory oligonucleotide; Drug
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Santa Monica, California • Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Colon Cancer, Rectal Cancer, Colorectal Cancer, Colorectal Cancer (CRC)
Interventions: fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Denver, Colorado • Arlington Heights, Illinois • Columbia, Maryland + 11 more

Conditions: Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
Interventions: Modified GCN+TTF treatment; Combination Product
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Neoplasms
Interventions: ADH300004; Drug
Lead sponsor: Adherex Technologies, Inc.; Industry
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage III Colorectal Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Unresectable Digestive System Adenocarcinoma, Unresectable Pancreatic Carcinoma
Interventions: Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Carcinoid, Neuroendocrine Tumors
Interventions: EPO906 epothilone B; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 5
States / cities: Chicago, Illinois • Iowa City, Iowa • New Orleans, Louisiana + 2 more

Conditions: Gastric Cancer, Metastatic
Interventions: TGFBR2 KO CAR27/IL-15 NK cells, Rimiducid (AP1903), Fludarabine, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions: Enzelkitug, Atezolizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions: selumetinib, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Tampa, Florida • Atlanta, Georgia • Chapel Hill, North Carolina + 3 more

Conditions: Colorectal Cancer
Interventions: Capecitabine and Cetuximab; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions: LY4052031, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Colorectal Carcinoma
Interventions: MGD007; Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: New Haven, Connecticut • Tampa, Florida • Baltimore, Maryland + 4 more

Conditions: Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions: Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Adult Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver
Interventions: Image-Guided Adaptive Radiation Therapy, Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diseases of Liver, Colon Carcinoma, Colorectal Carcinoma, Liver Metastases
Interventions: Computed Tomography Scan - 50% Dose Reduction, Computed Tomography Scan - 70% Dose Reduction, Deep Learning Image Reconstruction (DLIR); Diagnostic Test
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Cancer
Interventions: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 72 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced/Metastatic Solid Tumors
Interventions: NMS-03305293; Drug
Lead sponsor: Nerviano Medical Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: Ceralasertib, Olaparib, Durvalumab; Drug
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 3
States / cities: Duarte, California • San Francisco, California • Chicago, Illinois

Conditions: Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Tumors Metastatic to Brain
Interventions: cediranib maleate, whole-brain radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions: PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl); Drug
Lead sponsor: Egetis Therapeutics AB (publ); Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more

Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Wild-type Reovirus; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • The Bronx, New York + 2 more

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, leucovorin calcium; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 19
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 16 more

Conditions: Gallbladder Cancer, Biliary Tract Cancer
Interventions: Gemcitabine, Cisplatin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Pancreatic Ductal, Pancreatic Cancer, Pancreatic Disease
Interventions: AGS-1C4D4, Gemcitabine; Biological
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: La Jolla, California • Boynton Beach, Florida • Miami, Florida + 12 more

Search by objective public record fields.

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)

MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer

Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques

LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer

A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer